Form 4: Director Jasinski Acquires LMAT Shares via Vesting

LeMaitre Vascular Director Lawrence J. Jasinski acquired one share of common stock through the release of dividend equivalent rights, increasing his direct beneficial ownership to 4,774 shares.

Summary

• Director Lawrence J. Jasinski of LeMaitre Vascular, Inc. (LMAT) acquired 1 share of common stock on December 6, 2025.
• The acquisition occurred at a price of $0, indicating it was part of an equity compensation plan.
• This share was acquired upon the release of dividend equivalent rights (DERs) associated with a restricted stock unit (RSU) award granted on December 6, 2024.
• Following this transaction, Jasinski directly beneficially owns 4,774 shares of LMAT common stock.
• Additionally, several dividend equivalent rights were acquired on December 4, 2025, associated with various RSU and performance share unit (PSU) awards granted between 2022 and 2024, which vest proportionately with their underlying awards.

Sentiment

Score: 6

Explanation: The filing reports a routine insider transaction where a director acquired shares through the vesting of equity awards. This is a neutral to slightly positive event as it increases the director's direct ownership, aligning interests, but does not indicate new strategic developments or significant financial performance.

Positives

• Director Jasinski's beneficial ownership of common stock increased by 1 share, demonstrating continued equity interest in the company.
• The acquisition of shares through the vesting of awards indicates the successful progression of previously granted equity compensation, aligning management interests with shareholders.

Future Outlook

This filing is a routine insider transaction report and does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• Represents shares acquired upon release of dividend equivalent rights, as reported in Table II, on a one-for-one basis.
• These dividend equivalent rights accrued on a restricted stock unit award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
• These dividend equivalent rights were released in connection with the vesting of a restricted stock unit award granted on 12/6/2024. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

Industry Context

This Form 4 filing reports a standard insider equity transaction, specifically the vesting and acquisition of shares by a director. Such transactions are common in the medical device industry, where equity compensation is a key component of executive and director remuneration, aligning their interests with shareholders. It does not provide broader industry trends or competitive analysis.

Comparison to Industry Standards

• The acquisition of shares through the vesting of equity awards is a standard practice for executive and director compensation across the medical device industry, similar to companies like Medtronic, Boston Scientific, or Abbott Laboratories, where long-term incentives often include RSUs and PSUs.
• The $0 acquisition price for shares obtained via vesting is typical for equity compensation plans, reflecting the conversion of rights into actual shares rather than a cash purchase.

Corporate Governance

Stakeholder Impact

• Shareholders: The increase in director's beneficial ownership aligns management interests with shareholders, potentially signaling confidence in the company's long-term prospects.
• Employees: The vesting of equity awards is a standard component of compensation, which can positively impact employee morale and retention for those with similar compensation structures.

Next Steps

• Continued vesting of remaining dividend equivalent rights and underlying restricted stock unit and performance share unit awards as per their respective schedules.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the vesting of equity awards and the acquisition of a small number of shares by a director. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transaction is an expected part of executive compensation and does not indicate a significant shift in company fundamentals or market sentiment. Therefore, a 'hold' recommendation is appropriate as there's no new catalyst for a 'buy' or 'sell' decision based solely on this filing.

Keywords

LeMaitre Vascular, LMAT, Form 4, Insider Transaction, Beneficial Ownership, Director, Equity Compensation, Restricted Stock Units, Performance Share Units, Dividend Equivalent Rights